By Sherri Oslick --
About
Court Report: Each week we will report briefly on recently filed
biotech and pharma cases, and a few interesting cases will be selected
for periodic monitoring.
Genzyme Corp. v. Lupin Ltd. et al.
1:09-cv-00147; filed March 5, 2009 in the District Court of Delaware
Infringement of U.S. Patent Nos. 5,496,545 ("Phosphate-Binding Polymers for Oral Administration," issued March 5, 1996), 5,667,775 ("Phosphate-Binding Polymers for Oral Administration," issued on September 16, 1997), 6,509,013 ("Method of Making Phosphate-Binding Polymers for Oral Administration," issued January 21, 2003), and 7,014,846 ("Phosphate-Binding Polymers For Oral Administration," issued on March 21, 2006) following a Paragraph IV certification as part of Lupin's filing of an ANDA to manufacture a generic version of Genzyme's Renagel® (sevelamer hydrochloride, used for the control of serum phosphorus in patients with chronic kidney disease on dialysis). View the complaint here.
Procter & Gamble Co. et al. v. Apotex Inc. et al.
1:09-cv-00143; filed March 4, 2009 in the District Court of Delaware
Infringement of U.S. Patent No. 7,192,938 ("Method of Treatment Using Bisphosphonic Acid," issued March 20, 2007) following a Paragraph IV certification as part of Apotex's filing of an ANDA to manufacture a generic version of P&G's Actonel® (risedronate sodium, used to treat and prevent postmenopausal osteoporosis). View the complaint here.
Galderma Laboratories LP et al. v. Tolmar Inc.
3:09-cv-00400; filed March 3, 2009 in the Northern District of Texas
Infringement of U.S. Patent Nos. 6,881,726 ("Aqueous Compositions Containing Metronidazole," issued April 19, 2005) and 7,348,317 (same title, issued March 25, 2008), both licensed exclusively to Galderma, following a Paragraph IV certification as part of Tolmar's filing of an ANDA to manufacture a generic version of Galderman's MetroGel® (metronidazole gel, used to treat rosacea). View the complaint here.
Duramed Pharmaceuticals, Inc. v. Paddock Laboratories, Inc.
1:09-cv-01905, filed March 2, 2009 in the Southern District of New York
Infringement of U.S. Patent No. 5,908,638 ("Pharmaceutical Compositions of Conjugated Estrogens and Methods for Their Use," issued June 1, 1999) following a Paragraph IV certification as part of Paddock's filing of an ANDA to manufacture a generic version of Duramed's Cenestin® (synthetic conjugated estrogens, used to peri-menopausal, menopausal, and post-menopausal disorders). View the complaint here.
Millennium Pharmaceuticals Inc. v. Teva Parenteral Medicines Inc. et al.
1:09-cv-00127; filed February 27, 2009 in the District Court of Delaware
Infringement of U.S. Patent Nos. 6,713,446 ("Formulation of Boronic Acid Compounds," issued March 30, 2004) and 6,958,319 (same title, issued October 25, 2005), licensed exclusively to Millennium, following a Paragraph IV certification as part of Teva's filing of an ANDA to manufacture a generic version of Millenium's Velcade® (bortezomib, used to treat multiply myeloma). View the complaint here.
Merck & Co., Inc. v. Sandoz Inc.
3:09-cv-00890; filed February 27, 2009 in the District Court of New Jersey
Infringement of U.S. Patent Nos. 5,719,147 ("Morpholine and Thiomorpholine Tachykinin Receptor Antagonists," issued February 17, 1998), 6,048,859 (same title, issued April 11, 2000), 6,096,742 ("Polymorphic Form of a Tachykinin Receptor Antagonist," issued August 1, 2000), and 6,235,735 ("Morpholine and Thiomorpholine Tachykinin Receptor Antagonists, issued May 22, 2001) following a Paragraph IV certification as part of Sandoz's filing of an ANDA to manufacture a generic version of Merck's Emend® (aprepitant, used to prevent nausea and vomiting caused by chemotherapy). View the complaint here.
Schering Corp. v. Mylan Pharmaceuticals Inc.
3:09-cv-00874; filed February 26, 2009 in the District Court of New Jersey
Infringement of U.S. Patent No. 7,405,223 ("Treating Allergic and Inflammatory Conditions," issued July 29, 2008) following a Paragraph IV certification as part of Mylan's amendment of its ANDA to manufacture a generic version of Schering-Plough's Clarinex® (desloratidine, used to treat allergies). View the complaint here.
AstraZeneca Pharmaceuticals LP et al. v. Sandoz Inc.
3:09-cv-00870; filed February 26, 2009 in the District Court of New Jersey
Infringement of U.S. Patent No. 4,879,288 ("Novel Dibenzothiazepine Antipsychotic," issued November 7, 1989) following a Paragraph IV certification as part of Sandoz's filing of an amendment to its ANDA (adding additional dosage forms) to manufacture a generic version of AstraZeneca's Seroquel® XR (quetiapine fumarate, used to treat schizophrenia and bipolar disorder). View the complaint here.
Comments